DOCSLIB.ORG

Orphan Drug Designation List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orphan Drug Designation List Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 (-)-(3aR,4S,7aR)-4-Hydroxy-4- m-tolylethynyl-octahydro- Novartis indole-1-carboxylic acid Pharmaceuticals methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. 2 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono 3 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-bromoethyl) Threshold diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. 4 (1OR)-7-amino-12-fluoro- 2,10,16-trimethyl-15 oxo- 10,15,16,17-tetrahydro-2H-8,4- Treatment of anaplastic (metheno)pyrazolo[4,3- lymphoma kinase (ALK)-positive h][2,5,11]benzoxadiazacyclote or ROS1-positive non-small cell tradecine-3-carbonitrile n/a 6/23/2015 lung cancer Pfizer, Inc. 5 (1R,3R,4R,5S)-3-O-[2-O- Treatment of vaso-occlusive benzoyl-3-O-(sodium(2S)-3- crisis in patients with sickle cell cyclohexyl-propanoate- n/a 2/17/2009 disease. Pfizer, Inc. 6 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of T-cell non- Mundipharma ribitol-hydrochloride n/a 1/29/2004 Hodgkin's lymphoma Research Limited 7 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of acute Mundipharma ribitol-hydrochloride n/a 8/13/2004 lymphoblastic leukemia Research Limited Page 1 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Treatment of chronic lymphocytic leukemia and related leukemias to include (1S)-1-(9-deazahypoxanthin-9- prolymphocytic leukemia, adult T- yl)-1,4-dideoxy-1,4-imino-D- cell leukemia, and hairy cell Mundipharma ribitol-hydrochloride n/a 8/10/2004 leukemia Research Ltd. 9 (1S,3S)-3-amino-4- (difluoromethylene)cyclopenta necarboxylic acid hydrochloride, (1S,3S)-3-amino- 4-difluoromethylenyl-1- cyclopentanoic acid Catalyst hydrochloride n/a 9/15/2010 Treatment of infantile spasms. Pharmaceuticals, Inc. 10 (2'R,3'S)-2'-hydroxy-N-carboxy- 3'-amino-5'-methyl-hexanoic,N- tert-butyl ester, 13 ester 5B-20- epoxy-1B,2a,4a,7B,9a,10a,13a- heptahydroxy-4,10-diacetate-2- benzoate-(1"S)-7,9-acrolein Treatment of progressive Cortice Biosciences, acetal-11(15-1)-abeotaxane n/a 6/23/2014 supranuclear palsy Inc. 11 (2,2-diphenyl-tetrahydro-furan- 3-yl-methyl)-dimethylamine Anavex Life Sciences hydrochloride n/a 5/18/2016 Treatment of Rett Syndrome. Corporation 12 (2-(2-chlorophenyl)-4-[3- (dimethylamino)phenyl]-5- methyl-1h-pyrazolo [4,3-c] Genkyotex Innovation pyridine-3,6(2h,5h)-dione) n/a 10/14/2015 Treatment of systemic sclerosis. SAS Page 2 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 13 (2E, 4E, 6Z, 8E)-3,7-dimethyl-9- (2,6,6-trimethylcyclohex-1-en-l- yl) nona-2,4,6,8-tetraen-l-yl Treatment of retinitis acetate n/a 12/2/2010 pigmentosa QLT Inc. 14 Treatment of Leber congential amaurosis (LCA) due to inherited mutations in RPE65 (encoding (2E,4E,6Z,8E)-3,7-dimethyl-9- the protein retinal pigment (2,6,6-trimethylcyclohex-1- epithelial protein 65) or LRAT enyl)nona-2,4,6,8-tetraenyl (encoding the enzyme acetate 9-cis-retinyl acetate lecithin:retinol (API) n/a 12/2/2010 acyltransferase)genes. QLT, Inc. 15 (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7- (methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8- yl]oxy}acetyl)amino]-2-(4- hydroxyphenyl)acetyl]amino}b Treatment of primary biliary utanoic acid n/a 10/31/2012 cirrhosis Albireo AB 16 (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7- (methylthio)-1,1-dioxido-5- phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8- yl]oxy}acetyl)amino]-2-(4- hydroxyphenyl)acetyl]amino}b Treatment of progressive familial utanoic acid n/a 10/31/2012 intrahepatic cholestatis Albireo AB Page 3 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 17 (2Z)-2-cyano-3-3hydroxy-N-[4- Prevention of acute rejection (trifluoromethly)phenyl]-2- following kidney, heart, and liver Fujisawa Healthcare, hepten-6-ynamide Fk778 1/10/2005 transplantation Inc. 18 (3,5-Bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl- pyrimidin-2-yl amino) phenyl] NATCO Pharma benzamide n/a 3/18/2011 Treatment of pancreatic cancer Limited 19 (3,5-Bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl- pyrimidin-2-yl amino) phenyl] Treatment of chronic NATCO Pharma benzamide n/a 3/18/2011 myelogenous leukemia. Limited 20 (3,5-Bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl- pyrimidin-2-yl amino) phenyl] NATCO Pharma benzamideNRC-AN-019 n/a 3/18/2011 Treatment of Glioma Limited 21 (3E,5E)-3,5-bis[(4-fluoro-3- nitrophenyl)methylidene]-1- (prop-2-enoyl)azepan-4-0ne n/a 4/30/2014 Treatment of multiple myeloma VivoLux AB 22 (3S)-(+)-(5-chloro-2- methoxyphenyl)-1,3-dihydro-3- Centre National de la fluoro-6-(trifluoromethyl)-2H- Recherche indol-2-one n/a 12/9/2015 Treatment of Fragile X Syndrome. Scientifique (CNRS) 23 (3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3- thiazol-4-yl]propan-2- yl}carbamate n/a 9/11/2014 Treatment of Gaucher disease Genzyme Page 4 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 24 (3S)-1-azabicylo[2.2.2]oct-3yl {2-[2-(4-fluorophenyl)-1,3- thiazol-4-yl]propan-2- yl}carbamate n/a 8/26/2014 Treatment of Fabry's disease Genzyme Corporation 25 (3S)-3-(4- trifluoromethoxybenzyloxy)-6- nitro-2H-3,4- Global Alliance for TB dihydroimidazo[2,1-b]oxazine n/a 7/5/2007 Treatment of tuberculosis Drug Development 26 (3S)-3-[(2S)-2-({N-[2-tert- butyl)phenyl]carbamoyl}carbo nylamino) propanoylamino]-4- oxo-5-(2,3,5,6- Treatment of patients Pfizer Global tetrafluorophenoxy) pentanoci undergoing solid organ Research and acid n/a 8/19/2003 transplantation. Development 27 (3S)-3-[({1-(2-Chlorobenzyl)-4- hydroxy-5-methyl-2-oxo-1,2- dihydropyridin- 3yl}amino)carbonyl]amino-3- (4-methylphenyl)propanoic For mobilization of Aviara acid monosodium salt n/a 4/25/2016 hematopoietic stem cells Pharmaceuticals, Inc/ Page 5 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 28 (4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7- (dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1- dioxido-1-benzothiepin-5- yl]phenoxy]methyl]phenyl]met hyl]-4-aza-l- azoniabicyclo[2.2.2]octane Treatment of primary sclerosing Shire Human Genetic Chloride n/a 9/4/2013 cholangitis Therapies, Inc. 29 (4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7- (dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1- dioxido-1-benzothiepin-5- yl]phenoxy]methyl]phenyl]met hyl]-4-aza-l- azoniabicyclo[2.2.2]octane Treatment of primary biliary Shire Human Genetic Chloride n/a 9/4/2013 cirrhosis Therapies, Inc. 30 (4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7- (dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1- dioxido-1-benzothiepin-5- yl]phenoxy]methyl]phenyl]met hyl]-4-aza-l- azoniabicyclo[2.2.2]octane Shire Human Genetic Chloride n/a 9/4/2013 Treatment of alagille syndrome Therapies, Inc. Page 6 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 31 (4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7- (dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1- dioxido-1-benzothiepin-5- yl]phenoxy]methyl]phenyl]met hyl]-4-aza-l- azoniabicyclo[2.2.2]octane Treatment of progressive familial Shire Human Genetic Chloride n/a 9/4/2013 intrahepatic cholestasis Therapies, Inc. 32 (5R)-5-(4-{[2- fluorophenyl)methyl]oxy}phen yl)-L-prolinamide, Treatment of trigeminal Convergence hydrochloride n/a 7/24/2013 neuralgia Pharmaceuticals Ltd. 33 (5S,8S, 10aR)-N-benzhydryl-5- ((S)-2- (methylamino)propanamido)-3- (3-methylbutanoyl)-6- oxodecahydropyrrolo[1,2- a][1,5] diazocine-8- DebioPharm carboxyamide n/a 4/14/2016 Treatment of ovarian cancer International SA 34 (6- maleimidocaproyl)hydrazone of doxorubicin n/a 6/29/2011 Treatment of soft tissue sarcoma CytRx Corporation 35 (6-[4-Deoxy-4-[(2E,4E)- Parenteral treatment of painful, tetradecadienoylglycyl] amino- chronic, chemotherapy-induced L-glyceroB-L-manno- peripheral neuropathy that is heptopyranosyl]amino-9H- refractory to conventional DARA BioSciences, purine) n/a 2/21/2014 analgesics Inc. Page 7 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 36 (6aR, 10aR)-3-(1’,1’- dimethylheptyl)-delta8- tetrahydro-cannabinol-9- Corbus carboxylic acid n/a 10/13/2015 Treatment of cystic fibrosis.
Load more

Recommended publications
  • Clinical Protocol
    OncoMed Pharmaceuticals, Inc. Demcizumab CLINICAL PROTOCOL Protocol No. M18-006 Title: YOSEMITE: A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Version: 23 October 2014 Amendment 1: 24 November 2014 Amendment 2: 10 February 2015 Amendment 3: 28 May 2015 Amendment 4: 31 March 2016 Amendment 5: 19 December 2016 EudraCT Number: 2014‐003355‐56 Sponsor: OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, CA 94063 Phone: 650-995-8200 CONFIDENTIAL This document contains proprietary and confidential information of OncoMed Pharmaceuticals, Inc. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of OncoMed Pharmaceuticals, Inc. with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards/Ethics Committees under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws; however, OncoMed Pharmaceuticals, Inc. shall be promptly notified of any such disclosure. Protocol M18-006, Amendment 5 Page 1 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc. Demcizumab SPONSOR CONTACTS Medical Monitor: ___________________ (Primary) ___________________________ Email: ___________________ Phone: ____________________ Medical Monitor: ___________________ (Secondary) ___________________ Email: ___________________ Phone: ___________________ Safety Reporting: Europe, Australia Phone: ___________________ Fax: ___________________ United States Phone: ___________________ Fax: ___________________ Protocol M18-006, Amendment 5 Page 2 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc.
    [Show full text]
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 45: 279-297, 2020 Precision medicine for human cancers with Notch signaling dysregulation (Review) MASUKO KATOH1 and MASARU KATOH2 1M & M PrecMed, Tokyo 113-0033; 2Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan Received September 16, 2019; Accepted November 20, 2019 DOI: 10.3892/ijmm.2019.4418 Abstract. NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are conjugate (ADC) Rova-T, and DLL3-targeting chimeric antigen transmembrane receptors that transduce juxtacrine signals of receptor‑modified T cells (CAR‑Ts), AMG 119, are promising the delta-like canonical Notch ligand (DLL)1, DLL3, DLL4, anti-cancer therapeutics, as are other ADCs or CAR-Ts targeting jagged canonical Notch ligand (JAG)1 and JAG2. Canonical tumor necrosis factor receptor superfamily member 17, Notch signaling activates the transcription of BMI1 proto-onco- CD19, CD22, CD30, CD79B, CD205, Claudin 18.2, fibro- gene polycomb ring finger, cyclin D1, CD44, cyclin dependent blast growth factor receptor (FGFR)2, FGFR3, receptor-type kinase inhibitor 1A, hes family bHLH transcription factor 1, tyrosine-protein kinase FLT3, HER2, hepatocyte growth factor hes related family bHLH transcription factor with YRPW receptor, NECTIN4, inactive tyrosine-protein kinase 7, inac- motif 1, MYC, NOTCH3, RE1 silencing transcription factor and tive tyrosine-protein kinase transmembrane receptor ROR1 transcription factor 7 in a cellular context-dependent manner, and tumor-associated calcium signal transducer 2. ADCs and while non-canonical Notch signaling activates NF-κB and Rac CAR-Ts could alter the therapeutic framework for refractory family small GTPase 1. Notch signaling is aberrantly activated cancers, especially diffuse-type gastric cancer, ovarian cancer in breast cancer, non-small-cell lung cancer and hematological and pancreatic cancer with peritoneal dissemination.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Cancer Subtype Identification Using Somatic Mutation Data
    www.nature.com/bjc ARTICLE Genetics and Genomics Cancer subtype identification using somatic mutation data Marieke Lydia Kuijjer 1,2, Joseph Nathaniel Paulson1,2,3, Peter Salzman4, Wei Ding5 and John Quackenbush1,2,6 BACKGROUND: With the onset of next-generation sequencing technologies, we have made great progress in identifying recurrent mutational drivers of cancer. As cancer tissues are now frequently screened for specific sets of mutations, a large amount of samples has become available for analysis. Classification of patients with similar mutation profiles may help identifying subgroups of patients who might benefit from specific types of treatment. However, classification based on somatic mutations is challenging due to the sparseness and heterogeneity of the data. METHODS: Here we describe a new method to de-sparsify somatic mutation data using biological pathways. We applied this method to 23 cancer types from The Cancer Genome Atlas, including samples from 5805 primary tumours. RESULTS: We show that, for most cancer types, de-sparsified mutation data associate with phenotypic data. We identify poor prognostic subtypes in three cancer types, which are associated with mutations in signal transduction pathways for which targeted treatment options are available. We identify subtype–drug associations for 14 additional subtypes. Finally, we perform a pan-cancer subtyping analysis and identify nine pan-cancer subtypes, which associate with mutations in four overarching sets of biological pathways. CONCLUSIONS: This study is an important step toward understanding mutational patterns in cancer. British Journal of Cancer (2018) 118:1492–1501; https://doi.org/10.1038/s41416-018-0109-7 INTRODUCTION However, subtype classification using somatic mutations in Cancer is a heterogeneous disease that can develop in different cancer is challenging, mainly because the data are very sparse: tissues and cell types.
    [Show full text]
  • Abstract Book – Oral Sessions
    Sunday, June 21, 2015 12:00 p.m. - 1:15 p.m. Latin American Psychopharmacology Update: INNOVATIVE TREATMENTS IN PSYCHIATRY INNOVATIVE TREATMENTS IN PSYCHIATRY Flavio Kapczinski, The University of Texas Health Science Center at Houston Overall Abstract In this panel, we will propose innovative treatments in psychiatry and recent literature findings will be summarized. The effective pharmacological treatment of psychiatric diseases and development of new therapeutic entities has been a long-standing challenge. Despite the complexity and heterogeneity of psychiatric disorders, basic and clinical research studies and technological advancements in genomics, biomarkers, and imaging have begun to elucidate the pathophysiology of etiological complexity of psychiatric diseases and to identify efficacious new agents (Tcheremissine et al. 2014). Many psychiatric illnesses are associated with neuronal atrophy, characterized by loss of synaptic connections, increase of inflammatory markers like TNF-α and DAMPS (damage-associate molecular patterns,- cell free (ccf) DNA, heat shock proteins HSP70, HSP90, and HSP60, and cytochrome C), decrease of neurotrophic factors, increase of oxidative stress, mitochondrial dysfunction and apoptosis (Fries et al., 2012; Pfaffenseller et al., 2014). Also, neurocognitive impairment and poor psychosocial functioning has been related to a psychiatric disease. Therefore, trying to discover new therapeutic targets that act in these pathways can help to develop new treatment or improve the treatment of these serious diseases.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Safety and Tolerability of Arimoclomol in Patients with Sporadic Inclusion Body Myositis: a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial
    Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept trial Sporadic inclusion body myositis (IBM) is the commonest idiopathic inflammatory myopathy (IIM) occurring in patients over the age of 50 years.1-4 The prevalence of IBM differs between different populations and ethnic groups, with estimates between 4.9-70.6 per million population.5-10 IBM is distinguished from the other IIM by early asymmetric finger flexor and knee extensor weakness (leading to loss of hand function and propensity to fall) and resistance to immunosuppressive therapy. Any skeletal muscle can be affected, including oesophageal and pharyngeal muscles. Late-stage disease can be characterized by very significant morbidity including disability and loss of quality of life. Death in IBM is related to malnutrition, cachexia, aspiration, respiratory infection and respiratory failure, as a consequence of dysphagia, severe global weakness and weakness of the respiratory muscles.1-4 In a Dutch cohort, end-of-life care interventions were used by 13% of patients with IBM, highlighting the morbidity experienced by these patients and the need of supportive and palliative care in this disease.2 The aetiopathogenesis of IBM remains uncertain. The varied pathological findings observed have driven a number of theories including viral infection, accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic reticulum stress and impairment of autophagy and proteasomal proteolysis.11-15 Muscle biopsies from patients with IBM typically show several different pathological features broadly described as inflammatory or degenerative. Inflammatory features include endomysial infiltration by mononuclear cells (predominantly CD8+ T- cells), which surround and invade otherwise normal appearing muscle fibres, and overexpression of major histocompatibility complex (MHC) class I, which is not constitutively expressed by skeletal muscle.
    [Show full text]
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials
    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
    [Show full text]
  • Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in Vivo
    Author Manuscript Published OnlineFirst on December 3, 2010; DOI: 10.1158/1078-0432.CCR-10-1123 AuthorPublished manuscripts OnlineFirst have been on peer December reviewed and 3, accepted 2010 as for 10.1158/1078-0432.CCR-10-1123 publication but have not yet been edited. Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in vivo Peramaiyan Rajendran1, Tina H. Ong2, Luxi Chen1,3, Feng Li1, Muthu K Shanmugam1, Shireen Vali4, Taher Abbasi4, Shweta Kapoor4, Ashish Sharma4, Alan Prem Kumar1,3, Kam M. Hui2,5 Gautam Sethi1,5 1Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, 2Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research National Cancer Centre, Singapore 169610, 3Cancer Science Institute of Singapore, National University of Singapore, and 4Cellworks Group Inc., California 95070; 4Cellworks Research India Pvt. Ltd, Bangalore 560066, India. Running title: Butein inhibits STAT3 signaling in vitro and in vivo in HCC. 5To whom correspondence should be addressed: 1. Dr. Gautam Sethi, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Phone: +65-65163267; Fax: +65- 68737690; Email: [email protected] Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2010 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 3, 2010; DOI: 10.1158/1078-0432.CCR-10-1123 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Irina Nicoleta Cimalla Algan/Gan Sensors for Direct Monitoring Of
    Irina Nicoleta Cimalla AlGaN/GaN sensors for direct monitoring of fluids and bioreactions AlGaN/GaN sensors for direct monitoring of fluids and bioreactions Irina Nicoleta Cimalla Universitätsverlag Ilmenau 2011 Impressum Bibliografische Information der Deutschen Nationalbibliothek Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Angaben sind im Internet über http://dnb.d-nb.de abrufbar. Diese Arbeit hat der Fakultät für Elektrotechnik und Informationstechnik der Technischen Universität Ilmenau als Dissertation vorgelegen. Tag der Einreichung: 23. November 2009 1. Gutachter: PD Dr. rer. nat. habil. Andreas Schober (Technische Universität Ilmenau) 2. Gutachter: Univ.-Prof. Dr. rer. nat. habil. Oliver Ambacher (Fraunhofer Institut für Angewandte Festkörperphysik Freiburg) 3. Gutachter: PD Dr.-Ing. habil. Frank Schwierz (Technische Universität Ilmenau) Tag der Verteidigung: 15. Juli 2010 Technische Universität Ilmenau/Universitätsbibliothek Universitätsverlag Ilmenau Postfach 10 05 65 98684 Ilmenau www.tu-ilmenau.de/universitaetsverlag Herstellung und Auslieferung Verlagshaus Monsenstein und Vannerdat OHG Am Hawerkamp 31 48155 Münster www.mv-verlag.de ISBN 978-3-86360-003-7 (Druckausgabe) URN urn:nbn:de:gbv:ilm1-2010000519 Titelfoto: photocase.com | AlexFlint „Unde dragoste nu e, nimic nu e” „Wo Liebe nicht ist, ist gar nichts“ Marin Preda: „Cel mai iubit dintre pamanteni“ 5 6 Abstract In this thesis, AlGaN/GaN heterostructures, which have shown to be reliable pH sensors, have been characterized and further developed for the in situ monitoring of cell reactions. For this reason, NG108-15 nerve cells were cultivated on sensor surfaces and their response on different neuroinhibitors was clearly monitored. First, a measurement setup for extracellular recording was designed in connection with an improved chip design and sensor technology.
    [Show full text]